RAD51 testing shows promise in personalized early breast cancer treatment

by

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in tailoring treatment strategies in patients with early breast cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *